Targets for Phenylketonuria

Phenylketonuria (PKU) is a classical inborn error of metabolism caused primarily by mutations in the gene encoding phenylalanine hydroxylase (PAH), resulting in impaired conversion of phenylalanine to tyrosine. This leads to toxic accumulation of phenylalanine, causing neurotoxicity and intellectual disability if not managed. Understanding the molecular targets directly involved in PKU pathogenesis—specifically phenylalanine hydroxylase (PAH)—is fundamental for elucidating disease mechanisms, identifying actionable therapeutic strategies, and guiding drug development. Insights into PAH's structure, function, and regulation underpin the rationale for enzyme replacement, gene therapy, and small molecule chaperone approaches. Other targets, such as phenylalanine transporters, may modulate phenylalanine bioavailability and thus indirectly influence disease severity, but only those with a direct mechanistic role in PKU pathogenesis are considered here. Collectively, these targets provide a framework for precision medicine in PKU, from diagnosis to the development of novel treatments.

Phenylalanine Metabolism Enzymes

This category encompasses enzymes that are directly responsible for the catabolism of phenylalanine, most notably phenylalanine hydroxylase (PAH), which catalyzes the conversion of phenylalanine to tyrosine. Deficiency or dysfunction of PAH is the primary pathogenic mechanism in Phenylketonuria. Both the human (PAH) and mouse (Pah) orthologs are included, as they are mechanistically equivalent and serve as models for disease study and therapeutic development. These enzymes' malfunction leads directly to phenylalanine accumulation, neurotoxicity, and the clinical manifestations of PKU.

Phenylalanine Hydroxylase (PAH)

Phenylalanine Hydroxylase (PAH) is a hepatic enzyme encoded by the PAH gene (Entrez: 5053, KEGG: 5053, UniProt: P00439) that catalyzes the hydroxylation of L-phenylalanine to L-tyrosine using tetrahydrobiopterin (BH4) and molecular oxygen as cofactors. Structurally, PAH is a homotetramer with an N-terminal regulatory domain, a catalytic domain with an iron-binding site, and a C-terminal oligomerization domain. Regulation occurs via allosteric phenylalanine binding, phosphorylation, and cofactor (BH4) availability. Mutations in PAH result in reduced or absent enzyme activity, causing phenylalanine accumulation and subsequent neurotoxicity, the hallmark of PKU. The pathogenicity of PAH mutations has been extensively validated, with over 950 known pathogenic variants. Therapeutically, PAH is the target of enzyme substitution (pegvaliase), gene therapy, and BH4 supplementation (sapropterin dihydrochloride) in responsive genotypes. PAH activity is also a primary biomarker for diagnosis and monitoring. The central, direct role of PAH deficiency in PKU is supported by robust biochemical, genetic, and clinical evidence.

Phenylalanine Hydroxylase (Pah)

Phenylalanine Hydroxylase (Pah) is the murine ortholog of human PAH (Entrez: 18478, KEGG: 18478, UniProt: P16331), sharing high sequence and functional homology. The protein structure mirrors the human enzyme, with conserved regulatory, catalytic, and oligomerization domains. Mouse models with Pah mutations recapitulate key features of human PKU including hyperphenylalaninemia, cognitive impairment, and hypopigmentation, confirming the enzyme's pathogenic relevance. These models are instrumental for preclinical evaluation of gene therapy, enzyme substitution, and small molecule therapeutics. Like its human counterpart, Pah's direct deficiency leads to phenylalanine accumulation and neurotoxicity. Regulatory mechanisms and cofactor dependency are conserved, validating its use in translational research and drug development for PKU.